Skip to main content
Sign In

Resources For: Prospective Students | Current Students | Parents | Faculty & Staff | Alumni & Friends | Patients

 

Thomas W. Flaig, MD

Associate Professor
 Flaig Photo

Education:  MD

University of Minnesota, June 1999

Dr. Flaig completed his fellowship in 2006 at the University of Colorado Denver, after which he joined the faculty of the Divison of Medical Oncology at the University of Colorado Denver, Aurora, CO.

Research
Dr. Flaig is focused on translational genitourinary cancer research. He is a graduate of the University of Minnesota School of Medicine and completed the hematology/oncology fellowship program at the University of Colorado in 2006. The GU oncology clinic actively participates in cooperative (SWOG) and industry-sponsored clinical trials. His laboratory effort is split between new prostate cancer treatment approaches using natural products and the integration of targeted therapies into the treatment of bladder cancer, in addition to an active clinical practice treating all types of urologic cancers. 

Publications

  1. Flaig TW, Tangen CM, Hussain M, Stadler WM, Raghavan D, Crawford ED and Glodé LM.  Randomization reveals unexpected acute leukemias in SWOG prostate cancer trial.  Journal of Clinical Oncology. 2008; 26(9): 1532-6. PMID  18349405
  2. Flaig TW,  Costa L, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ , Drabkin HA.  Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.  British Journal of Cancer.  2010; 103 (6): 796-801.
  3. Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, and Glodé LM.  Adjuvant androgen deprivation for high risk prostate cancer after radical prostatectomy: Southwest oncology group (SWOG) Study S9921.  Journal of Clinical Oncology.2011; 29(15): 2040-5.  PMID 21502546.
  4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, KKheoh T, Haqq CM, Scher HI.  Abiraterone and Increased Survival in Metastatic Prostate Cancer.  New England Journal of Medicine. 2011; 364(21): 1995-2005.  PMID 21612468
  5. Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS.  The detection of circulation tumor cells in metastatic and clinically localized urothelial cancer.  Urology. 2011; 78(4):863-7.  PMID 21813167,  PMCID – pending
  6. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR.  A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.   Investigational New Drugs. 2013; 31(1):115-25.  PMID:22415798
  7. Yang X, Bemis L, Su L-J, Gao D, Flaig TW.  miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.  BioResearch Open Access. 2012, 1(2): 55-62.   PMID:23514806
  8. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS.  Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy.  New England Journal of Medicine.  2012; 367(13):1187-97.   PMID: 22894553
  9. Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW.  Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib. Clinical Genitourinary Cancer. 2012; 10(4): 225-31.  PMID: 23017335
  10. Yang X, Kessler E, Su, L Thorburn A, Frankel AE, Li Y,  La Rosa FG, Shen J, Li C, Varella-Garcia M, Glodé LM, Flaig TW.  Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer.  Clinical Cancer Research. 2012; 19(1): 148-57.  PMID:23172881
  11. Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy.  Nat Rev Clin Oncol. 2012; 10(1): 41-51.  PMID:23183631
  12.  Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy.  New England Journal of Medicine.  2013;368(2): 138-48.  PMID:23228172

 PubMed Articles

 

​